510(k) device
CMORE® CT System
Icotec AG · Posterior Cervical Screw System (NKG, Class II) · First FDA decision Nov 12, 2025, newest Nov 12, 2025Degenerative disc disease and spinal stenosis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
0
Naming "CMORE"
MAUDE reports
0
Brand "CMORE", since 2015
PubMed studies
25
Mentioning "CMORE"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing CMORE® CT System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- CMORE® CT System; CMORE® CT System Navigated InstrumentsBreakthrough510(k)
K252327 · Decided Nov 12, 2025 · 110 days after receipt
Device type: Posterior Cervical Screw System (NKG) · Orthopedic Surgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "CMORE", any status and sponsor, newest update first.
No registered device study names "CMORE".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "CMORE", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code NKG
2,234 reports: 765 malfunction, 1,452 injury, 15 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "CMORE"[tiab]. The summary above synthesizes these.
- A bacterial defense system targeting modified cytosine of phage genomic DNA.
Liu R, Tang D, Niu M, et al. · Nat Commun · 2026
- C-MORE: A high-content single-cell morphology recognition methodology for liquid biopsies toward personalized cardiovascular medicine.
Furkel J, Knoll M, Din S, et al. · Cell Rep Med · 2021Research Support, Non-U.S. Gov't
- Real-world evaluation of vascular complications and comorbidities in Portuguese patients with type 2 diabetes: Results from the cMORE study.
Alão S, Silva T, Leite AP, et al. · Rev Port Cardiol · 2024Multicenter Study, Research Support, Non-U.S. Gov't
- Cardiac Troponin I Antibodies Induce Cardiomyocyte Damage and Alter Cell Morphology.
Furkel J, Zirkenbach VA, Knoll M, et al. · Int J Mol Sci · 2025
- Coronary perforation incidence, outcomes and temporal trends (COPIT): a systematic review and meta-analysis.
Mikhail P, Howden N, Monjur M, et al. · Open Heart · 2022Meta-Analysis, Systematic Review
- The State of Overmedication in Borderline Personality Disorder: Interpersonal and Structural Factors.
Shapiro-Thompson R, Fineberg SK · Curr Treat Options Psychiatry · 2022
- Real-world evaluation of vascular complications and comorbidities in Portuguese patients with type 2 diabetes: Results from the cMORE study.
Bronze L · Rev Port Cardiol · 2024
- Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study.
Lancet Respir Med · 2023Observational Study, Multicenter Study
- See more with C-MORE: Addressing the need of robust cardiomyocyte morphological assessment.
Wardman R, Heineke J · Cell Rep Med · 2021Comment
- Markerless Motion Capture Enhances Clinical Assessments: Preliminary Validation with the Box and Blocks Test.
Farrens A, Chan V, Garcia-Fernandez L, et al. · IEEE Int Conf Rehabil Robot · 2025
- Reliability of multi-site UK Biobank MRI brain phenotypes for the assessment of neuropsychiatric complications of SARS-CoV-2 infection: The COVID-CNS travelling heads study.
Duff E, Zelaya F, Almagro FA, et al. · PLoS One · 2022Research Support, Non-U.S. Gov't
- Improved results of ACL primary repair in one-part tears with intact synovial coverage.
Ateschrang A, Schreiner AJ, Ahmad SS, et al. · Knee Surg Sports Traumatol Arthrosc · 2019
Other devices of this type
Also filed under product code NKG.
- M.U.S.T. MINI Posterior Cervical Screws System ExtensionMedacta International S.A. · 510(k) 2022
- Infinity OCT SystemMedtronic Sofamor Danek USA, Inc. · 510(k) 2026
- SYMPHONY OCT SystemMedos International SARL · 510(k) 2023
- QUARTEX® Occipito-Cervico-Thoracic Spinal System ExcelsiusGPS® InstrumentsGlobus Medical, Inc. · 510(k) 2024
- Centurion POCT SystemOrthofix, Inc. · 510(k) 2020
- PERLA® Posterior Occipito-Cervico-Thoracic Fixation SystemSpineart · 510(k) 2020
- Yukon OCT Spinal SystemK2m, Inc. · 510(k) 2020
- Connector SystemOrthofix, Inc. · 510(k) 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.